Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss

Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16

November 13, 2015 7:30 AM EST

PHILADELPHIA and OXFORD, United Kingdom, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the first quarter, which ended September 30, 2015.

The first quarter of our fiscal year was one of great progress for Adaptimmune as we made good headway toward our goal of delivering important T-cell therapy products to patients suffering from solid and hematologic cancers, commented James Noble, Adaptimmunes Chief Executive Officer. We continued the disciplined execution of our clinical programs, and are close to... More